
Sign up to save your podcasts
Or


In this episode, Professor Graham Collins shares with us the highlights in Hodgkin lymphoma from BSH 2025. He takes us through the ECHELON-1 trial, which led to the recent NICE approval of Brentuximab-AVD as a frontline treatment option for advanced stage Hodgkin lymphoma.
By British Society for HaematologyIn this episode, Professor Graham Collins shares with us the highlights in Hodgkin lymphoma from BSH 2025. He takes us through the ECHELON-1 trial, which led to the recent NICE approval of Brentuximab-AVD as a frontline treatment option for advanced stage Hodgkin lymphoma.

893 Listeners

27 Listeners

649 Listeners

2,787 Listeners

3 Listeners

53 Listeners

14,371 Listeners

3,148 Listeners

906 Listeners

49 Listeners

185 Listeners

33 Listeners

2,221 Listeners

1 Listeners

0 Listeners